BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer of cellular therapies for neurodegenerative diseases, ...

Clene will soon meet with the Food and Drug Administration to discuss analyses that could support an application for ...

The results of the MIROCALS randomized clinical trial have shown that adding low-dose interleukin-2 (IL2LD) to standard ...

Amyotrophic lateral sclerosis (ALS)—known as Lou Gehrig's Disease, based on the iconic 1930s New York Yankee baseball ...

A NEW PUBLICATION IN THE SCIENTIFIC JOURNAL PLOS ONE, SHOWS THAT MASITINIB CAN LOWER SERUM NEUROFILAMENT LIGHT CHAIN, AN IMPORTANT BIOMARKER FOR NEURODEGENERATIVE DISORDERS, INCLUDING MULTIPLE ...

The results of the MIROCALS randomised clinical trial showed that adding low-dose interleukin-2 (IL2LD) to standard treatment ...

Kolar Toyota ALS Fishing Tournament at the end of May includes a panel to talk about hopeful advancements in research.

ALS (also known as Motor Neuron Disease (MND)) affects around 45,000 people in Europe at any one time. It attacks the nerves ...

Home > Press release: Study launched to identify new ...

To more effectively treat neurodegenerative conditions, we first need diagnostic tools that lend a more complete picture of ...

Results of the MIROCALS (Modifying Immune Responses and Outcomes in ALS) clinical trial are published in The Lancet.